Data completeness
2/8 — Basic
PLEGINE (phendimetrazine tartrate) by Thayer Medical is clinical pharmacology phendimetrazine tartrate is a sympathomimetic amine with pharmacological activity similar to the prototype drugs of this class used in obesity, the amphetamines. Approved for the management of exogenous obesity.
Drug data last refreshed 1w ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
PLEGINE (phendimetrazine tartrate) is a sympathomimetic amine oral tablet indicated for the management of exogenous obesity. It acts as a CNS stimulant and appetite suppressant with a mechanism similar to amphetamines, though the exact action in obesity treatment remains incompletely established.
Pre-Launch
Pre-launch stage with no established commercial infrastructure; small company (Thayer Medical) suggests lean go-to-market team and exposure-building opportunities.
Mechanism of Action
CLINICAL PHARMACOLOGY Phendimetrazine tartrate is a sympathomimetic amine with pharmacological activity similar to the prototype drugs of this class used in obesity, the amphetamines. Actions include central nervous system stimulation and elevation of blood pressure. Tachyphylaxis and tolerance…
Worked on PLEGINE at Thayer Medical? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.